(JHX) James Hardie Industries - Ratings and Ratios
Fiber Cement, Fiber Gypsum, Cement Bonded Boards, Exterior Siding, Interior Linings
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 44.4% |
| Value at Risk 5%th | 61.3% |
| Relative Tail Risk | -16.19% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.88 |
| Alpha | -62.02 |
| CAGR/Max DD | -0.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.882 |
| Beta | 1.107 |
| Beta Downside | 0.936 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.26% |
| Mean DD | 19.17% |
| Median DD | 14.94% |
Description: JHX James Hardie Industries October 30, 2025
James Hardie Industries plc (NYSE:JHX) manufactures and sells fiber-cement, fiber-gypsum, and cement-bonded boards across the United States, Australia, Europe and New Zealand, organized into three reporting segments: North America Fiber Cement, Asia-Pacific Fiber Cement and Europe Building Products.
The company’s product suite-branded primarily as Hardie™ and supplemented by fermacell and AESTUVER-covers exterior siding, cladding, trim, soffit, and interior linings, with applications ranging from residential housing to industrial fire-protection solutions.
In FY 2023 the firm generated roughly $5.5 billion of revenue and delivered an adjusted EBITDA margin of about 20 %, reflecting strong demand for low-maintenance, fire-resistant building materials, especially in the U.S. residential market, which historically accounts for ~70 % of total sales.
Key macro drivers include U.S. housing starts (up ≈5 % YoY) and tightening building-code requirements that favor fiber-cement products; however, raw-material cost volatility-particularly silica sand and gypsum-adds upside risk to margins.
Assuming the current pace of U.S. construction activity persists, the North America segment could achieve double-digit revenue growth, but a sustained rise in mortgage rates or a slowdown in home-building permits would materially weaken that outlook.
For a data-rich, quantitative assessment of JHX’s valuation and risk profile, see the detailed analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (192.1m TTM) > 0 and > 6% of Revenue (6% = 247.0m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -5.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.78% (prev 18.59%; Δ 3.19pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 693.5m > Net Income 192.1m (YES >=105%, WARN >=100%) |
| Net Debt (4.66b) to EBITDA (734.8m) ratio: 6.34 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (577.4m) change vs 12m ago 33.56% (target <= -2.0% for YES) |
| Gross Margin 36.27% (prev 40.17%; Δ -3.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.24% (prev 79.14%; Δ -35.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.42 (EBITDA TTM 734.8m / Interest Expense TTM 128.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.40
| (A) 0.06 = (Total Current Assets 2.03b - Total Current Liabilities 1.13b) / Total Assets 14.07b |
| (B) 0.12 = Retained Earnings (Balance) 1.73b / Total Assets 14.07b |
| (C) 0.05 = EBIT TTM 437.4m / Avg Total Assets 9.52b |
| (D) 0.26 = Book Value of Equity 2.02b / Total Liabilities 7.75b |
| Total Rating: 1.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 54.55
| 1. Piotroski 2.50pt |
| 2. FCF Yield 1.95% |
| 3. FCF Margin 7.23% |
| 4. Debt/Equity 0.83 |
| 5. Debt/Ebitda 6.34 |
| 6. ROIC - WACC (= 3.41)% |
| 7. RoE 5.98% |
| 8. Rev. Trend 40.11% |
| 9. EPS Trend -63.41% |
What is the price of JHX shares?
Over the past week, the price has changed by +9.06%, over one month by -11.24%, over three months by -4.22% and over the past year by -46.75%.
Is JHX a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the JHX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.7 | 36.7% |
| Analysts Target Price | 26.7 | 36.7% |
| ValueRay Target Price | 18 | -8% |
JHX Fundamental Data Overview November 23, 2025
P/E Trailing = 42.4545
P/E Forward = 21.2766
P/S = 2.6283
P/B = 1.7115
P/EG = 2.5263
Beta = 0.847
Revenue TTM = 4.12b USD
EBIT TTM = 437.4m USD
EBITDA TTM = 734.8m USD
Long Term Debt = 4.97b USD (from longTermDebt, last quarter)
Short Term Debt = 77.0m USD (from shortTermDebt, last quarter)
Debt = 5.24b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.66b USD (from netDebt column, last quarter)
Enterprise Value = 15.29b USD (10.82b + Debt 5.24b - CCE 772.0m)
Interest Coverage Ratio = 3.42 (Ebit TTM 437.4m / Interest Expense TTM 128.0m)
FCF Yield = 1.95% (FCF TTM 297.7m / Enterprise Value 15.29b)
FCF Margin = 7.23% (FCF TTM 297.7m / Revenue TTM 4.12b)
Net Margin = 4.67% (Net Income TTM 192.1m / Revenue TTM 4.12b)
Gross Margin = 36.27% ((Revenue TTM 4.12b - Cost of Revenue TTM 2.62b) / Revenue TTM)
Gross Margin QoQ = 32.59% (prev 37.44%)
Tobins Q-Ratio = 1.09 (Enterprise Value 15.29b / Total Assets 14.07b)
Interest Expense / Debt = 1.29% (Interest Expense 67.8m / Debt 5.24b)
Taxrate = -39.50% (negative due to tax credits) (15.8m / -40.0m)
NOPAT = 610.2m (EBIT 437.4m * (1 - -39.50%)) [negative tax rate / tax credits]
Current Ratio = 1.79 (Total Current Assets 2.03b / Total Current Liabilities 1.13b)
Debt / Equity = 0.83 (Debt 5.24b / totalStockholderEquity, last quarter 6.32b)
Debt / EBITDA = 6.34 (Net Debt 4.66b / EBITDA 734.8m)
Debt / FCF = 15.64 (Net Debt 4.66b / FCF TTM 297.7m)
Total Stockholder Equity = 3.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.37% (Net Income 192.1m / Total Assets 14.07b)
RoE = 5.98% (Net Income TTM 192.1m / Total Stockholder Equity 3.21b)
RoCE = 5.35% (EBIT 437.4m / Capital Employed (Equity 3.21b + L.T.Debt 4.97b))
RoIC = 10.80% (NOPAT 610.2m / Invested Capital 5.65b)
WACC = 7.39% (E(10.82b)/V(16.06b) * Re(10.09%) + D(5.24b)/V(16.06b) * Rd(1.29%) * (1-Tc(-0.40)))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.58%
[DCF Debug] Terminal Value 70.53% ; FCFE base≈329.6m ; Y1≈318.6m ; Y5≈315.8m
Fair Price DCF = 6.94 (DCF Value 4.02b / Shares Outstanding 579.3m; 5y FCF grow -4.56% → 3.0% )
EPS Correlation: -63.41 | EPS CAGR: -50.75% | SUE: -2.75 | # QB: 0
Revenue Correlation: 40.11 | Revenue CAGR: 10.13% | SUE: 0.02 | # QB: 0
Additional Sources for JHX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle